How are these drugs administered? Is a genetic component more reactive to this therapy. Does this show promise?
Nivolumab + Ipilimumab for MCRPC - Advanced Prostate...
Nivolumab + Ipilimumab for MCRPC
![ronton2 profile image](https://images.hu-production.be/avatars/aa7d51c20f23b7d0950efa0d57be8043_small@2x_100x100.jpg)
Written by
![ronton2 profile image](https://images.hu-production.be/avatars/aa7d51c20f23b7d0950efa0d57be8043_small@2x_100x100.jpg)
ronton2
To view profiles and participate in discussions please or .
Read more about...
2 Replies
•
They are both administered iv. The combination was found to be highly toxic as tested. It had some but not much activity- some response in 10% in patients who'd already had chemo,and in 26% of patients who were chemo-naive. Response was better among patients who had higher levels of PD-L1 (≥1%), DNA damage repair defects(DDR), homologous recombination deficiency (HRD), or above-median tumor mutational burden (TMB). They stopped the trial and used more nivo and less ipi. We shall see if that helps.
As I've mentioned, the one time Opdivo + Yervoy + Keytruda combo was in situ 7 months following the hemi-cryoablation of the GL10 right half of prostate in Dec. 2015.
Not what you're looking for?
You may also like...
Nivolumab+docetaxel trial
and docetaxel only. Did you hear something about more encouraging results on this combo? My cancer...
Bone Marrow Transplant for MCRPC
Prostate Cancer'
https://clinicaltrials.gov/ct2/show/NCT02995330
I hear the the chance of dying...
Treatment change imminent for mcrpc
cancer was said to be “very aggressive” with scans showing mets in the right ribs and the right...